Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients

Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine ur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of hematology 2019-05, Vol.98 (5), p.1101-1110
Hauptverfasser: Chaloemwong, Juthatip, Tantiworawit, Adisak, Rattanathammethee, Thanawat, Chai-Adisaksopha, Chatree, Rattarittamrong, Ekarat, Norasetthada, Lalita, Charoenkwan, Pimlak, Louthrenoo, Worawit
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1110
container_issue 5
container_start_page 1101
container_title Annals of hematology
container_volume 98
creator Chaloemwong, Juthatip
Tantiworawit, Adisak
Rattanathammethee, Thanawat
Chai-Adisaksopha, Chatree
Rattarittamrong, Ekarat
Norasetthada, Lalita
Charoenkwan, Pimlak
Louthrenoo, Worawit
description Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. This was a cross-sectional study in patients aged 15 years or older at Chiang Mai University Hospital. All patients had blood and 24-h urine collection test. We enrolled 112 thalassemia patients in which 67.0% were female, 64.3% had beta thalassemia/Hb E, 76.8% were transfusion dependent, and 59.8% were post splenectomy. The median age was 29 (16–58) years. Mean SUA was 6.7 ± 2.0 mg/dl and hyperuricemia (SUA > 6.8 mg/dl) was found in 47 cases (45.2%). Intact spleen (ORs 4.3, 95%CI 1.55–12.50, p  = 0.01) and lower FEuric (ORs 2.08, 95%CI 1.35–3.33, p   700 mg/24 h) was found in 83.3%. UUA hyperexcretion patients had renal hyperfiltration 46%, glomerular dysfunction 84%, and tubular dysfunction 7.7%. From our study, hyperuricemia was found in approximately 40% of thalassemia patients but gouty arthritis occurred only in few patients (6%). This may be explained by urinary uric hyperexcretion which is found in over 80%. The significant risk factors for hyperuricemia were intact spleen and lower fraction excretion of uric acid.
doi_str_mv 10.1007/s00277-019-03630-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2210222695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2210222695</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-590d9bc2bbf845156350d6930e0032891d8b75919fb2bf6085c16dd26121d5b83</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouq7-AQ9S8OLB6mTSNM1RFr9A8KIHTyFNUu3SL5MW9N-bdVcFD-YwCfM-82Z4CTmicE4BxEUAQCFSoDIFljNIYYvMaMYwBV5k22QGksmUx7NH9kNYAlAsMtwlewwEUsbEjDzffgzOT742rq31WRJfnVtVk7h3491Y991Zojub6BB6U-vR2cT07dDURq_EkNRdMr7qJuori2SIbdeN4YDsVLoJ7nBzz8nT9dXj4ja9f7i5W1zepyYDOqZcgpWlwbKsioxTnjMONpcMHADDQlJblIJLKqsSyyqHghuaW4s5RWp5WbA5OV37Dr5_m1wYVVsH45pGd66fgkKkgIi55BE9-YMu-8l3cTuFVOQgQYgsUrimjO9D8K5Sg69b7T8UBbUKXq2DVzF49RV8rHNyvLGeytbZn5HvpCPA1kCIUvfi_O_f_9h-As7ijR8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2176090774</pqid></control><display><type>article</type><title>Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients</title><source>SpringerLink Journals - AutoHoldings</source><creator>Chaloemwong, Juthatip ; Tantiworawit, Adisak ; Rattanathammethee, Thanawat ; Chai-Adisaksopha, Chatree ; Rattarittamrong, Ekarat ; Norasetthada, Lalita ; Charoenkwan, Pimlak ; Louthrenoo, Worawit</creator><creatorcontrib>Chaloemwong, Juthatip ; Tantiworawit, Adisak ; Rattanathammethee, Thanawat ; Chai-Adisaksopha, Chatree ; Rattarittamrong, Ekarat ; Norasetthada, Lalita ; Charoenkwan, Pimlak ; Louthrenoo, Worawit</creatorcontrib><description>Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. This was a cross-sectional study in patients aged 15 years or older at Chiang Mai University Hospital. All patients had blood and 24-h urine collection test. We enrolled 112 thalassemia patients in which 67.0% were female, 64.3% had beta thalassemia/Hb E, 76.8% were transfusion dependent, and 59.8% were post splenectomy. The median age was 29 (16–58) years. Mean SUA was 6.7 ± 2.0 mg/dl and hyperuricemia (SUA &gt; 6.8 mg/dl) was found in 47 cases (45.2%). Intact spleen (ORs 4.3, 95%CI 1.55–12.50, p  = 0.01) and lower FEuric (ORs 2.08, 95%CI 1.35–3.33, p  &lt; 0.01) were associated with hyperuricemia significantly. Seven (6.3%) had gouty arthritis and nine (8%) had microscopic hematuria, one case being confirmed nephrolithiasis. The mean UUA excretion was 981.3 ± 335.0 mg/day and UUA hyperexcretion (&gt; 700 mg/24 h) was found in 83.3%. UUA hyperexcretion patients had renal hyperfiltration 46%, glomerular dysfunction 84%, and tubular dysfunction 7.7%. From our study, hyperuricemia was found in approximately 40% of thalassemia patients but gouty arthritis occurred only in few patients (6%). This may be explained by urinary uric hyperexcretion which is found in over 80%. The significant risk factors for hyperuricemia were intact spleen and lower fraction excretion of uric acid.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-019-03630-0</identifier><identifier>PMID: 30721337</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Arthritis ; Hematology ; Medicine ; Medicine &amp; Public Health ; Oncology ; Original Article ; Uric acid ; Urine</subject><ispartof>Annals of hematology, 2019-05, Vol.98 (5), p.1101-1110</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Annals of Hematology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-590d9bc2bbf845156350d6930e0032891d8b75919fb2bf6085c16dd26121d5b83</citedby><cites>FETCH-LOGICAL-c401t-590d9bc2bbf845156350d6930e0032891d8b75919fb2bf6085c16dd26121d5b83</cites><orcidid>0000-0002-2381-9292</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-019-03630-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-019-03630-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30721337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaloemwong, Juthatip</creatorcontrib><creatorcontrib>Tantiworawit, Adisak</creatorcontrib><creatorcontrib>Rattanathammethee, Thanawat</creatorcontrib><creatorcontrib>Chai-Adisaksopha, Chatree</creatorcontrib><creatorcontrib>Rattarittamrong, Ekarat</creatorcontrib><creatorcontrib>Norasetthada, Lalita</creatorcontrib><creatorcontrib>Charoenkwan, Pimlak</creatorcontrib><creatorcontrib>Louthrenoo, Worawit</creatorcontrib><title>Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. This was a cross-sectional study in patients aged 15 years or older at Chiang Mai University Hospital. All patients had blood and 24-h urine collection test. We enrolled 112 thalassemia patients in which 67.0% were female, 64.3% had beta thalassemia/Hb E, 76.8% were transfusion dependent, and 59.8% were post splenectomy. The median age was 29 (16–58) years. Mean SUA was 6.7 ± 2.0 mg/dl and hyperuricemia (SUA &gt; 6.8 mg/dl) was found in 47 cases (45.2%). Intact spleen (ORs 4.3, 95%CI 1.55–12.50, p  = 0.01) and lower FEuric (ORs 2.08, 95%CI 1.35–3.33, p  &lt; 0.01) were associated with hyperuricemia significantly. Seven (6.3%) had gouty arthritis and nine (8%) had microscopic hematuria, one case being confirmed nephrolithiasis. The mean UUA excretion was 981.3 ± 335.0 mg/day and UUA hyperexcretion (&gt; 700 mg/24 h) was found in 83.3%. UUA hyperexcretion patients had renal hyperfiltration 46%, glomerular dysfunction 84%, and tubular dysfunction 7.7%. From our study, hyperuricemia was found in approximately 40% of thalassemia patients but gouty arthritis occurred only in few patients (6%). This may be explained by urinary uric hyperexcretion which is found in over 80%. The significant risk factors for hyperuricemia were intact spleen and lower fraction excretion of uric acid.</description><subject>Arthritis</subject><subject>Hematology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Uric acid</subject><subject>Urine</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LxDAQhoMouq7-AQ9S8OLB6mTSNM1RFr9A8KIHTyFNUu3SL5MW9N-bdVcFD-YwCfM-82Z4CTmicE4BxEUAQCFSoDIFljNIYYvMaMYwBV5k22QGksmUx7NH9kNYAlAsMtwlewwEUsbEjDzffgzOT742rq31WRJfnVtVk7h3491Y991Zojub6BB6U-vR2cT07dDURq_EkNRdMr7qJuori2SIbdeN4YDsVLoJ7nBzz8nT9dXj4ja9f7i5W1zepyYDOqZcgpWlwbKsioxTnjMONpcMHADDQlJblIJLKqsSyyqHghuaW4s5RWp5WbA5OV37Dr5_m1wYVVsH45pGd66fgkKkgIi55BE9-YMu-8l3cTuFVOQgQYgsUrimjO9D8K5Sg69b7T8UBbUKXq2DVzF49RV8rHNyvLGeytbZn5HvpCPA1kCIUvfi_O_f_9h-As7ijR8</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Chaloemwong, Juthatip</creator><creator>Tantiworawit, Adisak</creator><creator>Rattanathammethee, Thanawat</creator><creator>Chai-Adisaksopha, Chatree</creator><creator>Rattarittamrong, Ekarat</creator><creator>Norasetthada, Lalita</creator><creator>Charoenkwan, Pimlak</creator><creator>Louthrenoo, Worawit</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2381-9292</orcidid></search><sort><creationdate>20190501</creationdate><title>Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients</title><author>Chaloemwong, Juthatip ; Tantiworawit, Adisak ; Rattanathammethee, Thanawat ; Chai-Adisaksopha, Chatree ; Rattarittamrong, Ekarat ; Norasetthada, Lalita ; Charoenkwan, Pimlak ; Louthrenoo, Worawit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-590d9bc2bbf845156350d6930e0032891d8b75919fb2bf6085c16dd26121d5b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Arthritis</topic><topic>Hematology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Uric acid</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaloemwong, Juthatip</creatorcontrib><creatorcontrib>Tantiworawit, Adisak</creatorcontrib><creatorcontrib>Rattanathammethee, Thanawat</creatorcontrib><creatorcontrib>Chai-Adisaksopha, Chatree</creatorcontrib><creatorcontrib>Rattarittamrong, Ekarat</creatorcontrib><creatorcontrib>Norasetthada, Lalita</creatorcontrib><creatorcontrib>Charoenkwan, Pimlak</creatorcontrib><creatorcontrib>Louthrenoo, Worawit</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaloemwong, Juthatip</au><au>Tantiworawit, Adisak</au><au>Rattanathammethee, Thanawat</au><au>Chai-Adisaksopha, Chatree</au><au>Rattarittamrong, Ekarat</au><au>Norasetthada, Lalita</au><au>Charoenkwan, Pimlak</au><au>Louthrenoo, Worawit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>98</volume><issue>5</issue><spage>1101</spage><epage>1110</epage><pages>1101-1110</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. This was a cross-sectional study in patients aged 15 years or older at Chiang Mai University Hospital. All patients had blood and 24-h urine collection test. We enrolled 112 thalassemia patients in which 67.0% were female, 64.3% had beta thalassemia/Hb E, 76.8% were transfusion dependent, and 59.8% were post splenectomy. The median age was 29 (16–58) years. Mean SUA was 6.7 ± 2.0 mg/dl and hyperuricemia (SUA &gt; 6.8 mg/dl) was found in 47 cases (45.2%). Intact spleen (ORs 4.3, 95%CI 1.55–12.50, p  = 0.01) and lower FEuric (ORs 2.08, 95%CI 1.35–3.33, p  &lt; 0.01) were associated with hyperuricemia significantly. Seven (6.3%) had gouty arthritis and nine (8%) had microscopic hematuria, one case being confirmed nephrolithiasis. The mean UUA excretion was 981.3 ± 335.0 mg/day and UUA hyperexcretion (&gt; 700 mg/24 h) was found in 83.3%. UUA hyperexcretion patients had renal hyperfiltration 46%, glomerular dysfunction 84%, and tubular dysfunction 7.7%. From our study, hyperuricemia was found in approximately 40% of thalassemia patients but gouty arthritis occurred only in few patients (6%). This may be explained by urinary uric hyperexcretion which is found in over 80%. The significant risk factors for hyperuricemia were intact spleen and lower fraction excretion of uric acid.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30721337</pmid><doi>10.1007/s00277-019-03630-0</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2381-9292</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0939-5555
ispartof Annals of hematology, 2019-05, Vol.98 (5), p.1101-1110
issn 0939-5555
1432-0584
language eng
recordid cdi_proquest_miscellaneous_2210222695
source SpringerLink Journals - AutoHoldings
subjects Arthritis
Hematology
Medicine
Medicine & Public Health
Oncology
Original Article
Uric acid
Urine
title Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A48%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperuricemia,%20urine%20uric%20excretion,%20and%20associated%20complications%20in%20thalassemia%20patients&rft.jtitle=Annals%20of%20hematology&rft.au=Chaloemwong,%20Juthatip&rft.date=2019-05-01&rft.volume=98&rft.issue=5&rft.spage=1101&rft.epage=1110&rft.pages=1101-1110&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-019-03630-0&rft_dat=%3Cproquest_cross%3E2210222695%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2176090774&rft_id=info:pmid/30721337&rfr_iscdi=true